
Pasithea Therapeutics Corp.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Pasithea Therapeutics Corp. is a biotechnology company developing drug therapies for neurological and psychiatric disorders, including ketamine-based intravenous infusion treatments and small-molecule compounds targeting conditions such as depression and autoimmune disease. The company also operates a drug discovery business supporting its internal pipeline and external research programs.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Coastlands Capital LP10% Owner | Buy | $411K | 875,000at $0.47 | Nov 17, 2026 |
| Coastlands Capital LP10% Owner | Buy | $291K | 583,083at $0.50 | Nov 16, 2026 |
| Coastlands Capital LP10% Owner | Buy | $104K | 209,431at $0.50 | Nov 13, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable KTTA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.